Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Subclinical thyrotoxicosis

E Marqusee1, S T Haden, R D Utiger

  • 1Harvard Medical School, Boston, Massachusetts, USA.

Endocrinology and Metabolism Clinics of North America
|April 16, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Osteoporosis: the hormone connection.

Health news (Waltham, Mass.)·2002
Same author

Estrogen, thyroxine binding in serum, and thyroxine therapy.

The New England journal of medicine·2001
Same author

The effect of droloxifene and estrogen on thyroid function in postmenopausal women.

The Journal of clinical endocrinology and metabolism·2000
Same author

Usefulness of ultrasonography in the management of nodular thyroid disease.

Annals of internal medicine·2000
Same author

Effects of age on serum dehydroepiandrosterone sulfate, IGF-I, and IL-6 levels in women.

Calcified tissue international·2000
Same author

Treatment of acromegaly.

The New England journal of medicine·2000
Same journal

Navigating Adrenal Disease: A Comprehensive, Practical Guide for the Clinician.

Endocrinology and metabolism clinics of North America·2026
Same journal

Adrenal Disorders in Pregnancy.

Endocrinology and metabolism clinics of North America·2026
Same journal

Diagnosis and Management of Adrenocortical Carcinoma.

Endocrinology and metabolism clinics of North America·2026
Same journal

Pheochromocytomas and Paragangliomas.

Endocrinology and metabolism clinics of North America·2026
Same journal

Hereditary Conditions Associated with Adrenocortical Carcinoma, Pheochromocytoma, and Other Adrenal Tumors: Genetic Testing and Management Recommendations.

Endocrinology and metabolism clinics of North America·2026
Same journal

Primary Bilateral Macronodular Adrenal Hyperplasia.

Endocrinology and metabolism clinics of North America·2026
See all related articles

Subclinical thyrotoxicosis, characterized by low thyroid-stimulating hormone (TSH) with normal thyroid hormones, often resolves spontaneously. Treatment decisions for this condition depend on the cause and patient

Area of Science:

  • Endocrinology
  • Thyroidology

Background:

  • Subclinical thyrotoxicosis is defined by suppressed serum thyrotropin (TSH) levels with normal circulating thyroid hormone concentrations.
  • It requires differentiation from nonthyroidal illness and secondary hypothyroidism.
  • Common etiologies include excessive thyroid hormone replacement, autonomously functioning thyroid nodules, multinodular goiter, and Graves' disease.

Purpose of the Study:

  • To outline the definition, differential diagnoses, and common causes of subclinical thyrotoxicosis.
  • To discuss the natural history, including the low likelihood of progression to overt thyrotoxicosis.
  • To provide guidance on treatment strategies based on etiology and clinical presentation.

Main Methods:

  • Literature review and synthesis of existing clinical guidelines and research.

Related Experiment Videos

  • Analysis of diagnostic criteria for subclinical thyrotoxicosis.
  • Evaluation of etiological factors and prognostic indicators.

    • Main Results:

    • Many patients with subclinical thyrotoxicosis exhibit no overt thyroid disease.
    • A minority may present with subtle hyperthyroid symptoms.
    • Spontaneous normalization of TSH levels occurs frequently over time.

    Conclusions:

    • Subclinical thyrotoxicosis has a generally benign prognosis with a low risk of progression.
    • Treatment should be individualized, considering the underlying cause, clinical signs of thyroid hormone excess, and potential risks to comorbid conditions.
    • Careful monitoring and judicious therapeutic intervention are recommended.